
Altimmune (ALT) Stock Forecast & Price Target
Altimmune (ALT) Analyst Ratings
Bulls say
Altimmune Inc. is positioned positively due to its promising product candidate, pemvidutide, which has demonstrated significant efficacy in reducing liver fat and improving key biomarkers associated with metabolic diseases, particularly in the treatment of obesity and metabolic-associated steatohepatitis (MASH). The product's favorable tolerability profile, coupled with its unique dual mechanism of action, enhances its potential to address not only hepatic inflammation but also systemic metabolic dysfunction, giving it a competitive edge in the biopharmaceutical market. Additionally, the FDA's willingness to consider non-invasive endpoints for conditions like alcoholic liver disease (ALD) may expedite regulatory approval, further strengthening the company's outlook.
Bears say
Altimmune has reported a significant net loss of $23.2 million in the fourth quarter of 2024, highlighting ongoing financial challenges as the company invests in the clinical development of pemvidutide. The current market landscape shows poor adoption of existing therapies, indicating potential compliance issues and skepticism regarding the effectiveness of treatments like pemvidutide, despite some weight loss results. Additionally, numerous risks associated with clinical development, competition, commercialization, and external factors compound the concerns surrounding the company's future financial performance.
This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.
Altimmune (ALT) Analyst Forecast & Price Prediction
Start investing in Altimmune (ALT)
Order type
Buy in
Order amount
Est. shares
0 shares